stockrow
Friday 6 November 2026
Export ARGX’s income statement to Excel — free account
argenex SE
ARGX Healthcare Biotechnology
argenex SE’s revenue for fiscal 2025 (year ended December 2025) was $4.2 billion, up 88.6% from fiscal 2024.
- Revenue
- +52.1%
- EPS
- +43.9%
- Free cash flow
- +537.5%
Quarter to September 2026, against a year earlier
920.33
25.56
+2.86%
Follow ARGX
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
31.77 | 33.47 | 30.23 | 39.97 |
+8 more quarters Free account |
P/S ratio |
10.15 | 10.85 | 9.53 | 12.13 | |
P/FCF ratio |
43.64 | 41.94 | 77.00 | 87.59 | |
P/Operating CF |
0.00 | 0.00 | 0.00 | 0.00 | |
P/B ratio |
7.15 | 6.87 | 6.19 | 7.04 | |
Price to Tangible BV |
7.38 | 7.09 | 6.43 | 7.31 | |
EV/Sales |
9.54 | 10.18 | 8.80 | 11.31 | |
EV/EBITDA |
32.52 | 33.86 | 31.96 | 45.61 | |
EV/Operating CF |
35.02 | 33.57 | 49.81 | 57.23 | |
EV/FCF |
41.04 | 39.34 | 71.08 | 81.66 | |
Quick Ratio |
— | 3.51 | — | 3.90 | |
Current Ratio |
— | 5.12 | — | 5.23 | |
Net Debt/EBITDA |
0.00 | (7.26) | 0.00 | (9.52) | |
Debt/Assets |
— | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
— | 0.00 | — | 0.00 | |
Asset Turnover |
0.00 | 0.72 | 0.00 | 0.64 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
— | (0.47) | — | (3.97) | |
Interest Coverage |
485.00 | 494.00 | 394.00 | 339.01 | |
Research and Development Expense of Revenue |
28.73% | 31.52% | 33.74% | 27.52% | |
Selling, General and Administrative Expense of Revenue |
34.15% | 27.04% | 27.04% | 32.50% | |
Intangible Assets out of Total Assets |
— | 0.03 | 0.00 | 0.03 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
0.11 | 0.11 | 0.12 | 0.11 | |
Graham Number |
0.00 | 290.25 | 0.00 | 237.82 | |
Earnings Yield |
3.15% | 2.99% | 3.31% | 2.50% | |
Free Cash Flow Yield |
2.29% | 2.38% | 1.30% | 1.14% | |
Revenue per Share |
27.91 | 24.75 | 21.16 | 21.59 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 57.52 | 0.00 | 56.95 | |
Shareholders Equity per Share |
0.00 | 135.08 | 0.00 | 119.47 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 135.08 | 0.00 | 119.47 | |
Free Cash Flow |
— | 643.00 | — | 573.51 | |
Working Capital |
— | 6,493.00 | — | 5,579.00 | |
Capital Expenditures |
— | (8.00) | — | (111.68) | |
Net Current Asset Value |
— | 6,453.00 | — | 5,539.00 | |
EV/EBIT |
32.52 | 33.86 | 31.96 | 45.61 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
34.58 | 36.09 | 34.62 | 48.91 | |
| Other line items | |||||
Average Receivables |
— | 1,298.28 | — | 1,078.14 | |
Average Payables |
— | 997.41 | — | 840.51 | |
Average Inventory |
— | 348.73 | — | 392.28 | |
Average Assets |
— | 7,414.28 | 0.00 | 6,612.73 | |
Average Common Equity |
— | 6,339.62 | — | 5,710.25 |
Columns are period end dates · fundamentals updated 2 Nov 2026